A collaborative research effort between the A*STAR Infectious Diseases Labs (A*STAR IDL) and the A*STAR Institute of High ...

A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer ...

One dose of the Jynneos vaccine was 58% effective against mpox infection overall and 84% in people without HIV, but only 35% ...

A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For ...

On August 13, 2024, the Africa Centres for Disease Control and Prevention (Africa CDC) declared the multi-country mpox ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

“The data presented here represent an important step forward in the evaluation of tecovirimat and in our understanding of mpox.” STOMP was led by Dr. Wilkin, Dr. Fischer, Jason ...

Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

recently presented data demonstrating that tecovirimat did not improve mpox resolution. The results from STOMP (Study of Tecovirimat for Mpox, also known as A5418) were shared as the oral ...